Overview

A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis

Status:
Completed
Trial end date:
2019-05-07
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biologic disease modifying antirheumatic drug (bDMARD) naïve participants with nonradiographic axial spondyloarthritis (nonrad-axSpA).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Ixekizumab